Dual targeting of Myc and apoptosis pathways for improved blood cancer treatment outcomes

Myc 和细胞凋亡途径的双重靶向可改善血癌治疗结果

• 批准号: nhmrc : GNT1122829
• 负责人: A/Pr Paul Watt
• 金额: $ 75.47万
• 依托单位: La Trobe University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/dual-targeting-myc-treatment-outcomes/1347300
• 关键词: Dual; targeting; Myc; apoptosis; pathways

Cancer cells frequently possess defects in genes called MYC and BCL-2 that control their growth and survival. Our preliminary studies have shown that combining novel reagents that specifically target MYC plus BCL-2 leads to enhanced lymphoma cell killing. In the proposed research, we will further develop these reagents and evaluate their ability to treat blood cancer in mice. We expect our approach will provide new avenues for treating cancer patients that respond poorly to current treatments.

癌细胞经常在控制其生长和存活的MYC和bcl-2基因中存在缺陷。我们的初步研究表明，结合针对MYC和bcl-2的新型试剂可以增强淋巴瘤细胞的杀伤作用。在这项拟议的研究中，我们将进一步开发这些试剂，并评估它们治疗小鼠血癌的能力。我们希望我们的方法将为治疗对当前治疗效果不佳的癌症患者提供新的途径。